A common hormonal condition affecting 10% to 13% of women has a new name and a new treatment approach. Polycystic ovary syndrome, now called polyendocrine metabolic ovarian syndrome (PMOS), is being recognized not as a reproductive disorder but as a metabolic disease. GLP-1 receptor agonists, the same class of drugs used for type 2 diabetes and weight loss, are emerging as a promising treatment option for women struggling with this condition.

What Is PMOS and Why Was It Misunderstood for So Long?

For decades, doctors focused on the wrong thing. The condition was named after polycystic ovaries, but experts now realize that polycystic ovaries were a red herring. "Instead of just a reproductive disorder, PCOS is much more of a metabolic disorder, characterized by elevated male hormones, insulin resistance, and glucose dysfunction," explained Karen Elkind-Hirsch, PhD, senior clinical scientist at Dexcom.

This misunderstanding has real consequences. About 70% of women with PMOS remain undiagnosed, according to the World Health Organization. The condition is driven by elevated insulin levels, which stimulate the ovaries to produce excess androgens, or male hormones. This creates a vicious cycle: hormonal dysregulation can cause obesity, and obesity can worsen hormonal dysregulation. Beyond fertility issues, the health stakes are high. Half of women with PCOS will develop type 2 diabetes by age 40, and the condition increases the risk of cardiovascular events like hypertension, stroke, and heart attack.

"People don't realize, in addition to weight gain, half of women with PCOS will develop type 2 diabetes by age 40. And with PCOS, there's an increased risk of cardiovascular events, like hypertension, stroke, and heart attack," said Lynsey Johnson, DNP, FNP-C, founder and CEO of PCOS Sisters Telehealth Clinic and Wellness Center.

Lynsey Johnson, DNP, FNP-C, founder and CEO of PCOS Sisters Telehealth Clinic and Wellness Center

How Did PMOS Treatment Evolve?

Treatment for PMOS has changed dramatically over the past few decades. In the past, doctors performed ovarian wedge resection surgery. Then came oral contraceptives to suppress androgen production and regulate menstrual cycles. When insulin resistance was recognized as central to the condition, metformin, a type 2 diabetes medication, became a standard treatment starting in the late 1990s and early 2000s.

Metformin does help with insulin resistance, menstrual regularity, and androgen levels, but it has a significant limitation: it does not produce meaningful weight loss. As obesity rates have climbed in the general population, PMOS symptoms have worsened and become more common. This gap in treatment effectiveness prompted researchers to explore GLP-1 receptor agonists as a solution.

What Does Research Show About GLP-1 Drugs for PMOS?

Multiple clinical trials have demonstrated that GLP-1 drugs outperform traditional treatments for weight loss and metabolic improvement in women with PMOS. Elkind-Hirsch led two landmark studies on this topic. In a 2022 study published in Fertility and Sterility, liraglutide, a GLP-1 drug, was superior to placebo in reducing body weight and improving cardiovascular and metabolic markers.

A second study, published in The Journal of Clinical Endocrinology and Metabolism in 2021, compared two combination treatments. Both combinations improved fasting glucose, testosterone, and blood pressure while significantly reducing weight and total body fat. However, the combination of exenatide, a GLP-1 drug, plus dapagliflozin, an SGLT2 inhibitor used for type 2 diabetes, was superior at improving blood glucose and insulin sensitivity compared to phentermine plus topiramate.

A third trial, led by Melanie Cree, MD, PhD, at the University of Colorado, compared Rybelsus, an oral version of semaglutide, with dietary intervention over four months in girls aged 12 to 21 with obesity and PMOS. Although results have not yet been peer-reviewed, patients lost more weight with the GLP-1 drug, and both treatments improved metabolic and reproductive measures.

The weight loss difference is striking. Patients on GLP-1 drugs typically lose about 10 pounds per month and experience drops in testosterone levels, compared to only 1 or 2 pounds per month on metformin alone.

How Should PMOS Treatment Be Personalized?

Not all women with PMOS look the same or have the same priorities. While 80% of women with PMOS are overweight or obese, 20% are not. Some women experience hair thinning, acne, and chin hair instead of weight gain. Others have irregular periods and skin issues. This variation means treatment must be tailored to each person's specific situation and goals.

"It's important to ask patients, 'What is important to you?' Instead, I get so many reports of 16-year-olds being told they will never get pregnant. After leaving the clinic, that comment affects their mental health, body image, and self-worth," said Sasha Ottey, MHA, MLS (ASCP), founder and executive director of PCOS Challenge: The National Polycystic Ovary Syndrome Association.

Sasha Ottey, MHA, MLS (ASCP), founder and executive director of PCOS Challenge: The National Polycystic Ovary Syndrome Association

Steps to Managing PMOS With Modern Treatment Options

• Assess Your Metabolic Health: Work with your doctor to evaluate insulin resistance, glucose levels, and androgen levels. These metabolic markers, not just ovarian appearance, define PMOS and guide treatment decisions.
• Consider Combination Therapy: Most people with PMOS today are on birth control, metformin, and/or semaglutide. Your doctor may recommend a combination approach tailored to your specific symptoms and health goals.
• Seek Comprehensive Support: Beyond medication, refer yourself to a dietitian, nutritionist, therapist, or psychiatrist depending on your individual needs. PMOS affects multiple body systems and mental health, so holistic care matters.
• Clarify Your Treatment Goals: Be clear with your healthcare provider about what matters most to you, whether that is fertility, weight loss, skin health, or cardiovascular risk reduction. This ensures your treatment plan aligns with your priorities.

Why Does the Name Change Matter?

In May 2026, The Lancet announced the official name change from polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome. This shift reflects a fundamental change in how the medical community understands the condition. The new name acknowledges that PMOS disrupts multiple hormone systems, causes ovulatory disturbances and infertility, and is metabolic in nature.

The name change is more than semantic. It signals that doctors should stop thinking of PMOS as primarily a reproductive problem and start treating it as a metabolic disease with reproductive consequences. This perspective shift opens the door to more effective treatments like GLP-1 drugs, which address the root cause of the condition: insulin resistance and hormonal dysregulation.

While PMOS cannot be cured, the expanding toolkit of treatments offers real hope. For women struggling with weight, irregular periods, fertility challenges, or the long-term health risks associated with this condition, GLP-1 drugs represent a significant advance in care. The key is working with healthcare providers who understand PMOS as a metabolic disorder and can personalize treatment to your unique situation and goals.